This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Top ETF Stories of March to Be Watched in April
by Sanghamitra Saha
Wall Street delivered a decent performance in March. With rates rising to start April, let's look at the key ETF stories of March that may hit headlines in April too.
5 Top-Performing ETF Areas of Last Week
by Sanghamitra Saha
Wall Street displayed a mixed performance last week.
5 Best ETF Areas of March
by Sanghamitra Saha
Wall Street offered decent returns in March. Marijuana, mining and cryptocurrency were the real winners in the month while some other spaces also rallied hard.
5 Sector ETFs That Beat the Market in March
by Sweta Killa
The month of March has been good for the U.S. stock market, with the three major bourses on track for the fifth consecutive month of gain.
Is Rescheduling a Certainty for Cannabis? ETFs That Surge
by Sanghamitra Saha
In a White House meeting, Vice President Kamala Harris this week urged the DEA to expedite the rescheduling of marijuana. President Biden also lately talked about ongoing efforts to review the federal classification of marijuana, hinting at his commitment to potential reforms
Cannabis ETFs Jump on Imminent Rescheduling News
by Sweta Killa
Cannabis stocks & ETFs jumped on Mar 15 after a prominent hedge fund manager suggested that regulators will soon reclassify marijuana as a less dangerous drug.
The Zacks Analyst Blog Highlights ARK Innovation ETF, ARK Genomic Revolution ETF, iShares U.S. Home Construction ETF, ETFMG Alternative Harvest ETF and iShares U.S. Regional Banks ETF
by Zacks Equity Research
ARK Innovation ETF, ARK Genomic Revolution ETF, iShares U.S. Home Construction ETF, ETFMG Alternative Harvest ETF and iShares U.S. Regional Banks ETF are included in this Analyst Blog.
5 Sector ETFs at the Forefront of the Market Rally Last Week
by Sweta Killa
Wall Street wrapped up the best week of 2023 to start November driven by increased investor confidence, buoyed by solid corporate earnings and signals that the Fed's aggressive interest rate hiking campaign might be nearing an end.
Time to Get High on Pot Stocks? (3 Catalysts)
by Andrew Rocco
When it comes to marijuana, a significant disconnect exists between the US government and the American people. Stock Strategist Andrew Rocco explains why the worst may be over for marijuana investors.
Cannabis ETFs Surge on Legalization Hopes: More Run Ahead?
by Sanghamitra Saha
The prospect of marijuana reclassification has injected newfound optimism into the cannabis investment landscape.
ETFs to Play Biden's 2024 Reelection Campaign Launch
by Sanghamitra Saha
President Joe Biden recently announced his reelection bid. These ETF areas may benefit on that campaign launch.
SAFE Banking Act Resurgence Boosts Pot ETFs: A New Era Ahead?
by Sanghamitra Saha
A fresh wave of investment opportunities emerges as the SAFE Banking Act is reintroduced to Congress, promising brighter prospects for marijuana stocks and ETFs.
ETF Areas to Win/Lose on Falling Biden's Approval Ratings
by Sanghamitra Saha
Biden's approval ratings are falling. These sectors ETFs may gain/lose amid this scenario.
Zacks Investment Ideas feature highlights: ETFMG Alternative Harvest ETF and Cronos Group
by Zacks Equity Research
ETFMG Alternative Harvest ETF and Cronos Group have been highlighted in this Investment Ideas article.
Are Marijuana Stocks A 'Buy' Amid U.S. Decriminalization Bill?
by Bryan Hayes
If signed into law, it would remove marijuana from the Controlled Substances Act (CSA).
Roundhill's Cannabis ETF (WEED) Launch Seems Timely
by Sanghamitra Saha
Roundhill Investments recently announced the launch of its own cannabis ETF, namely Roundhill Cannabis ETF (WEED).
Cannabis ETFs Set to Soar on Passage of Legalization Bill
by Sweta Killa
Cannabis stocks are poised to surge further especially following the legislation passed by the House to legalize marijuana nationwide.
Cannabis ETFs Soar Last Week
by Sweta Killa
Cannabis ETFs have topped the list of best performing ETFs last week on hopes of federal legalization vote.
After a Downbeat 2021, Will Marijuana ETFs Rebound in 2022?
by Sanghamitra Saha
Cannabis stocks and ETFs were massively downbeat in 2021. However, strong sales backdrop, growing medical usage and still-alive chances of a federal approval may cause a bounce back in pot ETFs in 2022.
The Zacks Analyst Blog Highlights: MJIN, NRGD, WANT, BZQ and MJ
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MJIN, NRGD, WANT, BZQ and MJ
4 Best-Performing Inverse/Leveraged ETFs of Last Week
by Sanghamitra Saha
Wall Street was mixed last week with the S&P 500 (up 0.32%), the Dow Jones (down 1.4%), the Nasdaq Composite (up 1.24%) and the Russell 2000 (down 2.85%) displaying a mixed performance.
Cannabis ETFs Soar on Republican-Led Legalization Bill
by Sweta Killa
Cannabis ETFs have gained momentum lately following the reports of a Republican-led bill, which is seeking to legalize marijuana at the federal level in the United States.
ETF Areas That Investors Can Consider for May
by Sweta Jaiswal, FRM
Considering the current market environment, we highlight some ETF areas for investors to bet on in May.
Cannabis ETFs to Surge on Banking Bill Approval in House
by Sanghamitra Saha
On Apr 19, the U.S. House of Representatives okayed legislation that would allow banks to provide services to cannabis companies in states where it is legal.
Cannabis On a Roll: Guide to ETF Investing
by Sanghamitra Saha
Shares of cannabis-related stocks and ETFs continue to be in good shape after a solid run last year.